Bionsight Enters R&D Collaboration Agreement with Astellas for First-in-Class Autoimmune Disorder Therapy

Bionsight Enters R&D Collaboration Agreement with Astellas for First-in-Class Autoimmune Disorder Therapy

Bionsight Enters R&D Collaboration Agreement with Astellas

Bionsight has entered into a global R&D collaboration agreement with Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo, Japan, to jointly develop a first-in-class therapy for autoimmune disorders.

The agreement took effect in November 2026. The project targets autoimmune disorders through the innate immune pathway, using a mechanism different from existing treatments, with the goal of delivering a preclinical candidate.

Bionsight leads the project, covering AI-driven molecular design, target validation on its Javelin platform, and lead optimization. Astellas contributes its data and expertise and provides development guidance and support.

Javelin analyzes how a drug interacts with more than 7,000 proteins at once, without chemically modifying the drug, and identifies where it binds.

The project has also been selected for the Global Collaboration R&D track of the 2026 SME Technology Innovation Development Program, run by the Korea Technology and Information Promotion Agency for SMEs (TIPA).

CEO Heejung Yang called the partnership “a significant milestone for Bionsight,” adding that the company aims to deliver innovative treatments for patients with autoimmune disorders.

https://apnews.com/press-release/ein-presswire-newsmatics/press-release-af60e393d82ee1f447de8d65cc7445cf

← Back to News